Spero Therapeutics (MEX:SPRO) Shiller PE Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SPRO Spero Therapeutics Inc MEX:SPRO
40 GF Score
Price MXN20.74
GF Value MXN13.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Spero Therapeutics Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Spero Therapeutics  (MEX:SPRO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Spero Therapeutics Shiller PE Ratio Related Terms


Spero Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Shiller PE Ratio Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:SPRO vs : Shiller PE Ratio Comparison

For the Biotechnology subindustry, Spero Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Shiller PE Ratio falls into.


MEX:SPRO
40GF Score
Spero Therapeutics Inc MEX:SPRO
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Spero Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Spero Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.792/333.9520*333.9520
=-2.792

Current CPI (Jun. 2026) = 333.9520.

Spero Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -21.693 241.428 -30.007
201612 -26.012 241.432 -35.980
201703 -20.326 243.801 -27.842
201706 -33.173 244.955 -45.225
201709 -16.358 246.819 -22.133
201712 -31.227 246.524 -42.301
201803 -13.444 249.554 -17.991
201806 -13.558 251.989 -17.968
201809 -11.223 252.439 -14.847
201812 -11.781 251.233 -15.660
201903 -5.625 254.202 -7.390
201906 -14.215 256.143 -18.533
201909 -18.755 256.759 -24.394
201912 -24.895 256.974 -32.352
202003 -28.607 258.115 -37.012
202006 -19.620 257.797 -25.416
202009 -18.998 260.280 -24.375
202012 -13.527 260.474 -17.343
202103 -13.491 264.877 -17.009
202106 -12.541 271.696 -15.415
202109 -14.393 274.310 -17.522
202112 -18.873 278.802 -22.606
202203 -20.110 287.504 -23.359
202206 -17.503 296.311 -19.726
202209 -6.638 296.808 -7.469
202212 10.723 296.797 12.065
202303 -4.506 301.836 -4.985
202306 -3.943 305.109 -4.316
202309 -1.045 307.789 -1.134
202312 16.465 306.746 17.925
202403 -3.983 312.332 -4.259
202406 -6.046 314.175 -6.427
202409 -6.301 315.301 -6.674
202412 -7.925 315.605 -8.386
202503 -5.115 319.799 -5.341
202506 -0.565 322.561 -0.585
202509 -2.385 324.800 -2.452
202512 9.543 324.054 9.834
202603 -2.344 330.213 -2.371
202606 -2.792 333.952 -2.792

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for MEX:SPRO:

  • Shiller PE Ratio:
  • GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Comparable Companies
Other Exchanges SPRO:USA2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score

Get the complete analysis for MEX:SPRO

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.74
Price
MXN13.54
GF Value